# Diffusion Pharmaceuticals

Source: https://onco.cc/companies/diffusion-pharmaceuticals/  
OnCo record `diffusion-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Diffusion developed trans sodium crocetinate, a small molecule meant to carry more oxygen into tumours so radiotherapy works better; its phase 3 trial in glioblastoma was cut short and the company merged into another biotech in 2023.

## Summary

Diffusion Pharmaceuticals, founded in 2001 in Charlottesville, Virginia, developed trans sodium crocetinate (TSC), a carotenoid derivative that increases oxygen diffusion into hypoxic tissue, as a radiosensitiser. Its phase 3 INTACT trial in newly diagnosed glioblastoma was terminated early, and the company merged with EIP Pharma in 2023. Its trials remain on ClinicalTrials.gov under Diffusion as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Diffusion Pharmaceuticals Inc; Diffusion Pharmaceuticals LLC
- Tags: ctgov-sponsor
- HQ: Charlottesville, VA
- Type: biotech
- Website: http://www.diffusionpharma.com

## Sources

- Official website: http://www.diffusionpharma.com
- ClinicalTrials.gov: trials led by Diffusion Pharmaceuticals Inc: https://clinicaltrials.gov/search?lead=Diffusion%20Pharmaceuticals%20Inc
- Wikidata: https://www.wikidata.org/wiki/Q5275432

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- fronts: [Radiation Therapy](https://onco.cc/fronts/radiation/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/diffusion-pharmaceuticals.json